IFF Targets Pet Health Boom with Canine-Specific Probiotic Launch
Event summary
- IFF introduced PureStrong™, a probiotic strain specifically designed for canine digestive health, on April 2, 2026.
- The product is part of IFF’s HOWARU® Pet portfolio, leveraging a single strain of Limosilactobacillus reuteri derived from the canine microbiome.
- A controlled study showed improved digestive health markers in dogs undergoing abrupt diet changes when using PureStrong™.
- The U.S. pet supplement market is valued at $3.2 billion, with nearly half of pet owners considering probiotics for their dogs.
The big picture
IFF’s launch of PureStrong™ reflects the growing premiumization of pet care, where owners increasingly treat pets as family members. The $3.2 billion U.S. pet supplement market is ripe for science-driven innovation, particularly in probiotics, where human-derived strains have dominated. IFF’s focus on canine-specific biology positions it to capitalize on this shift, though success will depend on convincing brands and consumers of the product’s unique advantages.
What we're watching
- Market Penetration
- How IFF will differentiate PureStrong™ in a crowded pet supplement market dominated by trend-driven formulations.
- Clinical Validation
- Whether the single-strain approach will gain broader acceptance among pet health brands and veterinarians.
- Category Expansion
- The pace at which IFF can extend the PureStrong™ model to other pet health segments beyond digestive care.
Our editorial coverage:
Related topics